Key result
Duchenne muscular dystrophy is linked to higher myocardial native T1 and ECV versus healthy controls.
Why the study?
Can CMR T1 and ECV mapping detect diffuse extracellular matrix expansion in DMD patients with normal LVEF and without LGE compared to healthy controls?
Observational (n=42)
No
Can CMR T1 and ECV mapping detect diffuse extracellular matrix expansion in DMD patients with normal LVEF and without LGE compared to healthy controls?
CMR T1 and ECV mapping can detect early, diffuse myocardial extracellular matrix expansion in DMD patients before the onset of LVEF decline or LGE, suggesting their potential as surrogate endpoints in clinical trials.
Answers are grounded in this paper and cite their sources.
May identify early myocardial changes in DMD with preserved LVEF; leaves open validation as surrogate endpoints in trials.
BACKGROUND: Duchenne muscular dystrophy (DMD) cardiomyopathy is a progressive disease for which there is no cure. Disease-specific therapies are needed that can be initiated before irreversible myocardial damage ensues. In order to evaluate therapeutic efficacy, surrogate endpoints other than ejection fraction must be found. The hypothesis of this study is that T1 and extracellular volume fraction (ECV) mapping using cardiovascular magnetic resonance (CMR) can detect diffuse extracellular matrix expansion in DMD patients with normal left ventricular ejection fraction (LVEF) and without myocardial late gadolinium enhancement (LGE). METHODS: Thirty-one DMD and 11 healthy control participants were prospectively enrolled. CMR using a modified Look-Locker (MOLLI) sequence was performed in all participants before and after contrast administration. T1 and ECV maps of the mid left ventricular myocardium were generated and regions of interest were contoured using the standard 6-segment AHA model. Global and segmental values were compared between DMD and controls using a Wilcoxon rank-sum test. RESULTS: The DMD participants had significantly higher mean native T1 compared with controls (1045 ms vs. 988 ms, p = 0.001). DMD participants with normal LVEF and without evidence of LGE also demonstrated elevated mean native T1 (1039 ms vs. 988 ms, p = 0.002, and 1038 ms vs. 988 ms, p = 0.011). DMD participants had a significantly greater mean ECV than controls (0.31 vs. 0.24, p < 0.001), even in the settings of normal LVEF (0.28 vs. 0.24, p < 0.001) and negative LGE (0.29 vs. 0.24, p = 0.001). CONCLUSIONS: DMD participants have elevated LV myocardial native T1 and ECV, even in the setting of normal LVEF and in the absence of LGE. T1 and ECV mapping in DMD have potential to serve as surrogate cardiomyopathy outcome measures for clinical trials.
No takes yet. Share an insight, caveat, or question.
Soslow et al. (2016) conducted an observational in Duchenne muscular dystrophy cardiomyopathy (n=42). Duchenne muscular dystrophy vs. Healthy controls was evaluated on Mean native T1 (p=0.001). Duchenne muscular dystrophy patients had higher mean myocardial native T1 (1045 ms vs 988 ms) and extracellular volume fraction compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: